Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:

• Wells Fargo Healthcare Conference in Boston, MA 
  Friday, September 5, 2025 
  One-on-one meetings only

• H.C. Wainwright Global Investment Conference in New York, NY 
  Tuesday, September 9, 2025 
  Fireside chat at 8:30 a.m. Eastern Time 
  The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

• Morgan Stanley Global Healthcare Conference in New York, NY
  Wednesday, September 10, 2025 
  Fireside chat at 7:45 a.m. Eastern Time 
  The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
[email protected]

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
[email protected]

Media Contact:
Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
[email protected] 

This press release was published by a CLEAR® Verified individual.

You May Also Be Interested In

• Crypto News Today: AlphaPepe Presale Nears Sellout With 11,000 Buyers While XRP Price Prediction Eyes $10
• Citizens Commission on Human Rights International Releases White Paper on Antidepressants and Psychiatric Drug Reform
• Partners Value Investments L.P. Announces Q2 2026 Interim Results